Actively Recruiting

Age: 18Years - 49Years
MALE
Healthy Volunteers
NCT07450027

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Led by Elazığ Mental Health and Diseases Hospital · Updated on 2026-03-04

120

Participants Needed

1

Research Sites

30 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.

CONDITIONS

Official Title

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Who Can Participate

Age: 18Years - 49Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of methamphetamine use disorder (MUD) or methamphetamine-induced psychotic disorder (MP) according to DSM-5-TR
  • Medication-free for at least one month prior to admission
  • Male aged 18 years or older and younger than 65 years
  • Provided informed consent
  • Healthy controls must have no psychiatric diagnosis or systemic/immunological illness
  • Healthy controls must be medication-free for at least one month prior to participation
Not Eligible

You will not qualify if you...

  • Presence of hypertension
  • Diabetes mellitus
  • Chronic kidney disease
  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Cardiac illness
  • Severe neurological disorders
  • Immunological or systemic illness
  • Primary psychiatric disorders other than MUD or MP
  • Alcohol use disorder for MUD and MP groups
  • Alcohol, drug, or substance use for healthy controls

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Elazığ Mental Health and Diseases Hospital

Elâzığ, Elâzığ, Turkey (Türkiye), 23200

Actively Recruiting

Loading map...

Research Team

M

Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here